GlaxoSmithKline plc has taken another important step back into the anticancer sector with the European Commission’s conditional approval of the company’s late-stage multiple myeloma therapy, Blenrep (belantamab mafodotin), announced on the 26 August.
The product is an antibody drug conjugate comprising a humanized anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to cytotoxic auristatin F, using drug linker technology licensed from Seattle...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?